1Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer.J Clin Oncol, 1999,17:485-493.
2Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase Ⅱ trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer, 2002,86:1367-1372.
3Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, Phase Ⅱ study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer, 2001,92:1759-1768.
4Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase Ⅱ study of oral capecitabine (Xeloda('')) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol, 2003,14:1227-1233.
5Abushullaih S, Saad ED, Munsell M, et al. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecita-bine: a single-institution experience. Cancer Invest, 2002,20:3-10.
6Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology, 2002,16:31-37.
7McMurrough J, McLeod HL. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol, 1996,41:425-427.
